MPM ASSET MANAGEMENT LLC
Q2 2022 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001263048
· CRD 148467
· SEC-registered investment adviser
$237.0M Reported Value Total
MPM BIOIMPACT reports 18 total accounts under management (AUM). There are 18 discretionary accounts valued at $1,695,048,827, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
34 funds
· $3.5B gross asset value
Other: $1.7B · Venture Capital Fund: $1.3B · Hedge Fund: $526.0M
Source: Form ADV filed 2026-04-28
Reported value
$237.0M
Quarter over quarter
-19.0%
Holdings
10
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Ansbert Karl Gadicke
MANAGING MEMBER
Todd Thomas Foley
MANAGING DIRECTOR
Brendan Michael Furey
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 11, 2022 |
| Form | 13F-HR |
| Reported value | $237.0M |
| Positions | 10 |
| Change in reported value | -19.0% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2025 13F
Filed Nov 14, 2025
|
4 | $44.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
5 | $43.3M |
|
Q1 2025 13F
Filed May 15, 2025
|
6 | $69.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
6 | $124.4M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
6 | $145.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $182.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
6 | $245.2M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
7 | $203.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
7 | $186.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
8 | $203.9M |
|
Q1 2023 13F
Filed May 12, 2023
|
9 | $240.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
9 | $239.0M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
9 | $262.6M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
10 | $237.0M |
|
Q1 2022 13F
Filed May 13, 2022
|
10 | $292.6M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
10 | $462.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
9 | $431.5M |
|
Q2 2021 13F
Filed Aug 13, 2021
|
9 | $537.9M |
|
Q1 2021 13F
Filed May 13, 2021
|
8 | $517.6M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
8 | $706.6M |
30 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ITOS iTeos Therapeutics, Inc. | $56.4M | 23.81% |
| 2 | TRDA Entrada Therapeutics, Inc. | $53.9M | 22.75% |
| 3 | DYN Dyne Therapeutics, Inc. | $34.0M | 14.35% |
| 4 | RPTX Repare Therapeutics, Inc. | $31.4M | 13.24% |
| 5 | AMYT Amryt Pharma plc | $18.7M | 7.87% |
| 6 | HOWL Werewolf Therapeutics, Inc. | $17.5M | 7.39% |
| 7 | TCRR TCR2 Therapeutics, Inc. | $11.7M | 4.96% |
| 8 | HARP Harpoon Therapeutics, Inc. | $6.0M | 2.52% |
| 9 | RYTM Rhythm Pharmaceuticals, Inc. | $3.8M | 1.59% |
| 10 | ONCR Oncorus, Inc. | $3.6M | 1.51% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.